Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Pegasys Market Size, Value And Growth Trajectory Through 2030
Historical growth was fueled by a rising incidence of chronic hepatitis infections, the extensive integration of interferon-based treatments, the validated clinical effectiveness of pegylated interferons, the expansion of antiviral therapies provided in hospitals, and the presence of standardized protocols for treatment.
The market expansion projected for the forecast period is partly due to the decreasing application of certain treatments, influenced by direct-acting antivirals, alongside an ongoing demand within particular patient groups. Furthermore, an intensified emphasis on individualized hepatitis treatment contributes to this growth, supported by the broadening of access initiatives in developing markets, as well as continuous clinical investigations into oncology applications.
Key trends for the forecast period encompass a heightened emphasis on extended-duration immunomodulatory treatments and a growing inclination towards dosing schedules that require less frequent administration. Also prominent are an increasing concentration on antiviral regimens involving multiple drugs, the broadening of drug formulations utilizing pegylation, and improved oversight of therapeutic results.
Get A Free Sample Report With In-Depth Market Insights:
Pegasys Market Growth Backed By Core Demand Fundamentals
The rising prevalence of hepatitis B is expected to drive the pegasys market. Hepatitis B is a viral infection that affects the liver, potentially leading to chronic conditions such as cirrhosis and liver cancer. The increasing incidence of Hepatitis B is fueled by factors including heightened transmission through unprotected sexual activity, intravenous drug use, and insufficient vaccination coverage in specific areas. Pegasys treats hepatitis B by enhancing the immune response to control viral replication and mitigate liver damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a Sweden-based government health agency, reported 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, which was a 78% increase from 16,187 cases recorded the year before. Additionally, the 2022 total of 28,420 cases represented a crude rate of 8.5 cases per 100,000 population. Consequently, the global increase in hepatitis B prevalence will significantly boost pegasys market growth. The rising healthcare expenditure is anticipated to fuel growth in the pegasys market. Healthcare spending represents financial investments by governments, private sectors, and organizations to support medical services, infrastructure, and public health initiatives. Globally, increasing healthcare expenditure is driven by factors such as the growing incidence of infectious diseases, the necessity to bolster healthcare systems, and the commitment to improve public health outcomes. Elevated healthcare spending supports Pegasys’s growth by facilitating greater investment in antiviral treatments, enhancing patient access to hepatitis therapies, and expanding funding for advanced biologic medicines. For instance, in May 2024, the Office for National Statistics, a UK-based statistics authority, reported that UK healthcare expenditure was approximately $359.16 billion (£292 billion) in 2023, with total healthcare expenditure increasing by 5.6% in nominal terms that year. Moreover, long-term health and social care expenditure grew by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure will boost growth in the pegasys market.
Pegasys Market Segment Analysis Spotlighting Growth Areas
The pegasys market covered in this report is segmented –
1) By Indication: Chronic Hepatitis C, Chronic Hepatitis B
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By End-Users: Hospitals, Clinics, Ambulatory Care, Home Care
Pegasys Market Growth Trends Reshaping The Competitive Landscape
A significant development in the Pegasys market revolves around extending its applications beyond its initial indications, specifically to include treatments for conditions such as polycythemia vera (PV) and essential thrombocythemia (ET). This approach aims to bolster its market presence and broaden its patient reach across the oncology and hematology domains. Pegasys is utilized to manage polycythemia vera (PV) and essential thrombocythemia (ET) by assisting in the regulation of abnormal blood cell production, as part of its wider therapeutic role in myeloproliferative neoplasms. For instance, in July 2024, pharmaand GmbH (pharma&), a pharmaceutical company based in Austria, obtained approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for a Type II variation for Pegasys (peginterferon alfa-2a), allowing its use as a treatment for all eligible patients with polycythemia vera (PV) or essential thrombocythemia (ET). Currently, Pegasys is approved by the EMA for addressing chronic hepatitis B (CHB) in adults and children aged 3 years and older, and chronic hepatitis C (CHC) in adults and children aged 5 years and older, when administered with other medicines. However, Pegasys has experienced expanded usage following its incorporation into independently developed oncology guidelines tailored for myeloproliferative neoplasms (MPNs), PV, and ET.
Pegasys Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the pegasys market are Roche Holding AG, pharmaand GmbH
View The Full Pegasys Market Report:
Pegasys Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the pegasys market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pegasys market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
